The process of commercializing a pharmaceutical product starts well before its launch. A comprehensive understanding of the market and competition is essential in order to successfully introduce a new drug. This knowledge allows you to strategically position your product for first-class outcomes.
‍
USPC offers a comprehensive understanding of the competitive landscape surrounding your drug and helps you stay informed about the activities of your competitors. This AI knowledge will enable you to strategize and develop unique selling points for your drug, increasing its chances of success in the market.

Once your new compound has received approval for human trials, it is crucial to intensify your efforts and dedicate resources to developing a comprehensive go-to-market strategy. While the primary focus for most manufacturers lies in conducting successful trials, it is essential to remember that the outcome of these trials will determine the future prospects of bringing your new drug to market.

To have a successful drug product launch USPC offers real-time competitive intel which includes pricing and market access AI analysis.

Moving into Phase II of the drug development process marks a critical turning point where the probability of drug approval significantly rises. It is imperative to allocate resources towards your market strategy. USPC will begin to delve deeper into market AI analytics in Phase II, concentrating on the necessary steps for successful product launch and sales. This includes planning for price strategies and the value proposition to ensure optimal market penetration.

USPC offers AI insight and guidance into commercial value-based pricing, comparable product intel, and real-world evidence & competing situations.

Once your compound has entered Phase III
and your study has been completed, your company can request FDA approval to market the drug. This is called a New Drug Application (NDA). The NDA contains all the scientific data that the company has gathered throughout the phases of all the trials.

USPC offers full commercialization capabilities which include aligning commercial operation goals leading your team in the execution of commercial strategies, minimizing time to market, and maximizing patient outcomes and brand performance.

After the FDA reviews safety and efficacy, your product is approved. Post-market studies are conducted to determine long-term safety and effectiveness and to identify adverse effects that may not have been apparent in prior trials. Phase 4 trials usually include thousands of participants.


For a successful launch, everything hinges on what we completed with Phases I, II, & III. USPC offers and integrates patient services, brand marketing, medical affairs, value proposition, field sales deployment, and trade market access services with a focus on EMR solutions.

The product launch and market acceptance creates a fortitude of challenges. USPC builds and offers sales and marketing capabilities to outperform the competitive landscape. USPC drives your business forward in a differentiated manner by elevating AI strategic launch capabilities leading to a competitive advantage.

Your company has made a massive investment and USPC offers the solution to capitalize on these investments by driving your product to the forefront of the patient journey. Inevitably, your profitability improves through a “Best-in-Class” partnership.